NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
QMIIZ ODT (meloxicam) by TerSera Therapeutics is cyclooxygenase inhibitors [moa]. Approved for osteoarthritis, rheumatoid arthritis. First approved in 2018.
Drug data last refreshed Yesterday
Mechanism of Action
Cyclooxygenase Inhibitors
Indications (2)
Clinical Trials (20)
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
Started Jun 2022
21 enrolled
Pregnancy Prevention
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
Started Oct 2018
26 enrolled
Healthy
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Started Sep 2013
28 enrolled
Arthritis, Rheumatoid
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Started Oct 2011
408 enrolled
Osteoarthritis of the Knee
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Started Nov 2008
6 enrolled
Healthy
Worked on QMIIZ ODT at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.